Skip to content

HomeLatest News
CompaniesExplore European Tech
ResearchAll published research
ThemesExplore the industries
Events & EarningsDates to follow
Our MissionLearn & Share

Join free Log in

Research

Research & articles Research Notes Company updates

Search research or companiesClear filters

CompanyCountryTechnologyPublication yearOrder

Official announcements retain their original headline and source language.

26 results

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Company updateOct 27, 2026Pharming Group N.V.Company newsroom

Pharming Group announces third quarter 2026 revenues above market expectations

Company updateOct 22, 2026Pharming Group N.V.Company newsroom

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Company updateOct 14, 2026Pharming Group N.V.Company newsroom

Pharming announces CEO transition

Company updateSep 29, 2026Pharming Group N.V.Company newsroom

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Company updateSep 25, 2026Pharming Group N.V.Company newsroom

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Company updateSep 22, 2026Pharming Group N.V.Company newsroom

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Company updateSep 11, 2026Pharming Group N.V.Company newsroom

Pharming Group to participate in September investor conferences

Company updateSep 9, 2026Pharming Group N.V.Company newsroom

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

Company updateAug 13, 2026Pharming Group N.V.Company newsroom

Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference

Company updateAug 4, 2026Pharming Group N.V.Company newsroom

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

Company updateJul 30, 2026Pharming Group N.V.Company newsroom

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

Company updateJul 16, 2026Pharming Group N.V.Company newsroom

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Company updateJun 4, 2026Pharming Group N.V.Company newsroom

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York

Company updateJun 2, 2026Pharming Group N.V.Company newsroom

Pharming Group announces results of 2026 Annual General Meeting of Shareholders

Company updateMay 28, 2026Pharming Group N.V.Company newsroom

European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union

Company updateMay 22, 2026Pharming Group N.V.Company newsroom

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026

Company updateMay 7, 2026Pharming Group N.V.Company newsroom

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

Company updateMay 7, 2026Pharming Group N.V.Company newsroom

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Company updateApr 23, 2026Pharming Group N.V.Company newsroom

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Company updateApr 16, 2026Pharming Group N.V.Company newsroom

Page 1 / 2Next

© 2026 European Tech Equities

X LinkedInSources Privacy Terms

Search companies & research

Search companies & research